The US Food and Drug Administration (FDA) is expected to have data next year that could lead to approval of a renal denervation device to lower blood pressurebut will the data be strong enough to sway skeptics?
Medscape interviewed three cardiologists to help answer this and other questions about this procedure, which is investigational in the United States but has the CE mark in Europe.
Renal denervationwhere nerves in the wall of the renal artery are ablated by applying radiofrequency pulses or ultrasound to the renal arteries, to blunt their activitydramatically lowered systolic blood pressure in early nonsham-controlled trials of patients with hypertension.[1]
However, enthusiasm for the procedure was dampened in 2014, when the SYMPLICITY HTN-3 trial[2] using the first-generation Symplicity (Medtronic; Minneapolis, Minnesota) catheter did not lead to better blood-pressure lowering than a sham procedure.
Since then, 3-month and 6-month outcomes from initial patients enrolled in three sham-controlled trials[3,4,5] of second-generation devices have hinted that the procedure confers a "modest" blood pressure-lowering benefit with no safety issues.
"I think there's once again excitement about renal artery denervation, and that it's justified," said Deepak Bhatt, MD, Brigham and Women's Hospital, Boston, Massachusetts, co-primary investigator of the SYMPLICITY HTN-3 trial, which in his words "basically caused a reset in the field."
However, "we just have to be careful to demand a high quality and quantity of data before jumping on board too soon," he told Medscape, "so that history doesn't repeat itself."
Felix Mahfoud, MD, University Hospital of Saarland, Saarland University, Homburg, Germany, was hopeful that the device would become available in the United States sometime next year, while noting that "[t]he pivotal studies are being completed [in 2020], and it depends on the FDA's review and approval."
Franz H. Messerli, MD, professor of medicine and cardiology at the University of Bern, Switzerland, told Medscape that "despite that I'm exposed to [the use of renal denervation, in Switzerland], I'm still not 100% convinced."
Since the field hit the reset button, the devices and procedure have evolved. Current second-generation devices include the Symplicity Spyral (Medtronic) multielectrode catheter that delivers radiofrequency energy to treat the renal arteries circumferentially and can ablate the distal renal artery and branch arteries, and the Paradise (ReCor Medical; Palo Alto, California) renal denervation system that uses ultrasound.
The RADIOSOUND-HTN trial,[6] published in January 2019, hinted at better blood pressure lowering with ultrasound versus radiofrequency ablation. However, principal investigator Philipp Lurz, MD, PhD, Heart Center Leipzig at University of Leipzig, Germany, told theheart.org | Medscape Cardiology at the time that "it is too early to prefer one technology over the other."
For Bhatt, "ultimately if this is really going to fly, it has to be something...where the majority of well-trained physicians can actually do it. That doesn't mean that training wouldn't be necessary."
A lot of strides have been made, he added, and "hopefully as the technology improves, technique will matter less," like going from balloon angioplasty to advanced-generation drug-eluting stents.
Messerli thinks the technique can be learned quickly, but that the disappointing results of SYMPLICITY HTN-3 showed that operators need experience to get good results.
He cited a number of reasons for his continued skepticism. First, studies so far suggest that there is a "glass ceiling" of a 6-mm Hg lowering of ambulatory systolic blood pressure[7]which is less than that obtained with current classes of antihypertensive medications.[8]
Second, patient responses vary greatly: In some, blood pressure drops but reverts to pretreatment levels after a few weeks, whereas in others, it stays lower longer.
Finally, there are no published clinical trial data beyond 3 years, and it is not clear whether the nerves may regenerate over time.
In contrast, Messerli said that if you give a patient antihypertensive medication, "blood pressure will be down within a few days...by about 10 to 12 mm Hg over 7 to 8 mm Hg," and it will stay down for the next week, month, year, or 10 years, "provided that the patient takes the tablet every day."
And it is well documented that "this [drug-induced] blood pressure reduction will reduce the risk for stroke, heart attack, and death over the next several years compared with no therapy."
So who might be eligible for the procedure if it were to gain FDA approval? According to Bhatt, if the ongoing pivotal trials are positive, catheter-based renal denervation may be considered for patients "who have high uncontrolled blood pressure that's prompting frequent hospital admissions."
However, he "and probably 99% of other referring physicians are going to be uncomfortable just doing a procedure on someone who could just be on a generic diuretic."
For Mahfoudwho practices in Germany, where the procedure is currently used"the ideal patient is [someone] with combined systolic and diastolic hypertension, a high heart rate, and a younger age."
Messerli noted that in Switzerland, the procedure is "not used intensely," but it is used to treat younger patients who have never been on antihypertensive therapy and who do not want to take pills (eg, a young man who is about to do his military service), or patients who still have elevated blood pressure despite being on three to five antihypertensive medications.
"I would want to see in the current series of randomized trials successfully completed, good safety data on longer-term follow-up, and durable results before premature approval," Bhatt reiterated. The ongoing two SPYRAL trials are "really the ones that will potentially lead to FDA approval," according to Bhatt (Table).
He speculates that the modest blood pressure lowering with renal denervation may underwhelm many referring physicians and third-party payors.
Mahfoud's hospital group first performed the procedure on patients 9 years ago, and he said that they plan to publish longer-term results, noting that certain patients have sustained blood pressure lowering.
AMBP = ambulatory blood pressure; BP = blood pressure; HTN = hypertension; SBP = systolic blood pressure
Recent optimism was spurred by the overall positive results from a meta-analysis of six sham-controlled randomized trials by Bhatt and others published in April 2019, as reported by theheart.org | Medscape Cardiology.[9]
In an accompanying editorial,[7] Sverre E. Kjeldsen, MD, PhD, Oslo University Hospital, Norway, and colleagues commented that despite the modest overall 6-mm Hg blood pressure-lowering effect, there is large variability in response, with 20%-30% of patients experiencing a "dramatic" decrease within 3 months after the procedure.
The editorialists speculate that "optimized patient selection and technical improvements may allow breaking the 'glass ceiling' of 6 mm Hg."
Similarly, a more recent review[10] by Mahfoud and others concluded that the current trials have established the safety and efficacy of the procedure, and "we must now define how [transcatheter renal denervation] will fit into a clinical practice."
The accompanying editorial for that review [11] agreed that final data from the pivotal trials may "convince the last skeptic, thereby paving the way to proceed with clinical use of" renal denervation.
The editorialists highlighted that "4 major questions remain...: 1) How does it work?; 2) Whom to treat?; 3) How to treat?; and 4) How long does it last?"
Dr Bhatt reports grant support/research contracts with Abbott Vascular, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo/Eli Lilly, Medtronic, Sanofi-Aventis, The Medicines Company, and Chiesi. Dr Messerli has disclosed no relevant financial relationships. Dr Mahfoud is supported by Deutsche Gesellschaft fr Kardiologie, Deutsche Hochdruckliga, and Deutsche Forschungsgemeinschaft and has received grant support and personal fees from Medtronic and ReCor Medical.
Follow theheart.org | Medscape Cardiology on Twitter
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
Read the original post:
Will Renal Denervation for Hypertension Rise Again? - Medscape
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]
- Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD - TCTMD - November 7th, 2019 [November 7th, 2019]